Skip to main content
British Journal of Cancer logoLink to British Journal of Cancer
. 1998 Mar;77(5):808–811. doi: 10.1038/bjc.1998.131

Dose-limiting neurotoxicity in a phase I study of penclomedine (NSC 388720, CRC 88-04), a synthetic alpha-picoline derivative, administered intravenously.

D I Jodrell 1, A Bowman 1, M Stewart 1, N Dunlop 1, R French 1, A MacLellan 1, J Cummings 1, J F Smyth 1
PMCID: PMC2149952  PMID: 9514062

Abstract

3,5-Dichloro-2,4-dimethoxy-6-(trichloromethyl)pyridine (penclomedine, NSC 338720, CRC 88-04) is an alpha-picoline derivative with anti-tumour activity in preclinical models. Penclomedine administration by 1-h intravenous infusion on 5 consecutive days was repeated 3 weekly in the absence of dose-limiting toxicity (DLT) or disease progression. Five dose levels were investigated (22.5-340 mg m(-2) day[-1]). Eight men and eight women were entered, median age 59 years (range 39-73 years), with good performance status (ECOG 0/1) in 11 patients. A total of 13 out of 16 patients had received previous chemotherapy. Common toxicity criteria grade (CTCg) II vomiting was recorded at all dose levels. Neurotoxicity (cerebellar ataxia and dizziness) was the DLT, CTCg III toxicity occurring in three out of three patients treated at 340 mg m(-2) day(-1). CTCg III dizziness was noted in one out of three patients at 250 mg m(-2) day(-1). Neurotoxicity developed during the 1-h infusion and persisted for a variable period (maximum 5 h) after infusion. Prophylactic antiemetic drugs appeared to reduce associated vomiting but did not prevent ataxia. No antiproliferative toxicities were noted and no anti-tumour responses were documented. Penclomedine pharmacokinetic studies confirmed preclinical evidence of extensive apparent distribution (93 l m[-2]) and rapid clearance (41 l h[-1] m[-2]). Purkinje cell loss has been identified in preclinical models after intraperitoneal administration (O'Reilly et al, 1996a) and further clinical development of penclomedine will focus on oral administration.

Full text

PDF
808

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Benvenuto J. A., Hittelman W. N., Zwelling L. A., Plunkett W., Pandita T. K., Farquhar D., Newman R. A. Biochemical pharmacology of penclomedine (NSC-338720). Biochem Pharmacol. 1995 Oct 12;50(8):1157–1164. doi: 10.1016/0006-2952(95)00251-t. [DOI] [PubMed] [Google Scholar]
  2. Harrison S. D., Jr, Plowman J., Dykes D. J., Waud W. R., Griswold D. P., Jr Preclinical antitumor activity of penclomedine in mice: cross-resistance, schedule dependence, and oral activity against tumor xenografts in brain. Cancer Res. 1991 Apr 15;51(8):1979–1983. [PubMed] [Google Scholar]
  3. Plowman J., Harrison S. D., Dykes D. J., Jr, Paull K. D., Narayanan V. L., Tobol H. K., Martin J., Griswold D. P., Jr Preclinical antitumor activity of an alpha-picoline derivative, penclomedine (NSC 338720), on human and murine tumors. Cancer Res. 1989 Apr 15;49(8):1909–1915. [PubMed] [Google Scholar]
  4. Prankerd R. J., Frank S. G., Stella V. J. Preliminary development and evaluation of a parenteral emulsion formulation of penclomedine (NSC-338720; 3,5-dichloro-2,4-dimethoxy-6-trichloromethylpyridine): a novel, practically water insoluble cytotoxic agent. J Parenter Sci Technol. 1988 May-Jun;42(3):76–81. [PubMed] [Google Scholar]
  5. Reid J. M., Mathiesen D. A., Benson L. M., Kuffel M. J., Ames M. M. Murine pharmacokinetics and metabolism of penclomedine [3,5-dichloro-2,4-dimethoxy-6-(trichloromethyl)pyridine, NSC 338720]. Cancer Res. 1992 May 15;52(10):2830–2834. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES